2022 World Conference on Lung Cancer (ePosters)-EP08.02-163. Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer

EP08.02-163. Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer

Pdf Summary

Amivantamab has shown potential as an effective treatment for EGFR-mutant non-small cell lung cancer (NSCLC), according to a real-world case series conducted at The University of Texas MD Anderson Cancer Center. The study analyzed data from patients with EGFR-mutant NSCLC who were treated with Amivantamab from May 2021 to January 2022.<br /><br />The results showed that Amivantamab could be an effective treatment option for patients with EGFR mutations outside of Exon 20 insertion mutations. Of the 16 patients included in the study, 10 (62.5%) showed initial clinical benefit. One patient with osimertinib-resistant Ex19DelT790M achieved a near-complete response with Amivantamab and has been on treatment for over 200 days.<br /><br />In terms of safety, the study also examined the use of radiation therapy (RT) concurrent with Amivantamab. Eight of the 16 patients received RT within 3 months before or after starting Amivantamab, and no additional safety concerns were reported for these cases. This suggests that RT can be safely used in combination with Amivantamab.<br /><br />The patients included in the study had various types of EGFR mutations, including Exon 20 insertion without T790M, classical mutations with and without T790M, atypical mutations, and amplification. Prior treatment included platinum-based chemotherapy, osimertinib, and poziotinib.<br /><br />Overall, these real-world case series findings provide further evidence for the efficacy and safety of Amivantamab in the treatment of EGFR-mutant NSCLC. While Amivantamab is currently approved for use in patients with EGFR Exon 20 insertion mutations, ongoing clinical trials are investigating its potential benefits in other EGFR-mutant NSCLC cases.

Asset Subtitle

Xiuning Le

Meta Tag

Speaker Xiuning Le

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Amivantamab

EGFR-mutant non-small cell lung cancer

treatment

real-world case series

University of Texas MD Anderson Cancer Center

EGFR mutations

Exon 20 insertion mutations

clinical benefit

radiation therapy

safety concerns